Psyence Biomedical Investor Presentation 2024

Psyence Biomedical Ltd., a biotech company focused on natural psilocybin drug development, presents its investor update for September 2024. The presentation outlines the company's plans for clinical trials and commercialization of its product candidate PEX 010 (25 mg). Key focus areas include regulatory approvals and clinical development progress in the psychedelics-based therapeutic space.